Fileni, C., Swoboda, D., Coltoff, A., Ali, N. A., Komrokji, R., Chan, O., Uy, G., Bertoli, S., Isidori, A., Clech, L. L., Heiblig, M., Gabellier, L., Lawrence, P., Kretschmer, L., Röllig, C., Lancet, J., Wei, A., Sallman, D., Cluzeau, T. (2025). Oral azacitidine maintenance improved survival for t-AML or AML-MR patients in first remission after CPX-351 and not eligible to HSCT. Blood. https://doi.org/10.1182/blood-2025-3441